TCG Labs Soleil Expands R&D with Additional $400M Funding

TCG Labs Soleil, a venture firm with an in-house biotech R&D hub, has announced an additional $400 million funding. This follows an initial $400 million raise in 2024, allowing the firm to foster single-asset portfolio companies toward clinical proof of concept and strategic partnerships. The integrated approach provides TCG Labs Soleil with authority over asset selection and financing, ensuring efficient decision-making and capital allocation. Since its inception, the firm has developed more than ten single-asset company portfolios, each targeting different therapeutic areas. The recent in-licensing deal by Juri Biosciences exemplifies its strategic advancement in acquiring innovative products. As part of its expansion, TCG Labs Soleil has established a presence in Shanghai to enhance its global R&D capabilities. The firm’s growth aligns with its mission to provide therapeutic solutions through a model merging venture capital and biotech. This setup, guided by top-tier scientists at Soleil and backed by The Column Group, strives to navigate single-asset programs through ideation, clinical proof, and partnering avenues, ultimately driving transformative medical breakthroughs.